Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.40 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066643 | 0.95 | IGF1R (0.42) | IGF1RNEK1FGFR1KDRPAK4 | |
| SCHEMBL26225584 | 0.84 | IGF1R (0.45) | IGF1RNEK1FGFR1KDRPAK4 | |
| SCHEMBL26226691 | 0.81 | IGF1R (0.49) | IGF1RNEK1FGFR1KDRPAK4 | |
| SCHEMBL26231136 | 0.81 | SYK (0.40) | IGF1RPAK4PAK1SYKSRC | |
| SCHEMBL26226735 | 0.81 | IGF1R (0.43) | IGF1RNEK1FGFR1KDRPAK4 | |
| SCHEMBL28800603 | 0.80 | NEK1 (0.39) | IGF1RNEK1FGFR1KDRPAK4 | |
| SCHEMBL14723204 | 0.79 | IGF1R (0.60) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL26225582 | 0.79 | IGF1R (0.36) | IGF1RFGFR1KDREGFRSRC | |
| SCHEMBL6385269 | 0.77 | SYK (0.37) | KMT2APAK4PAK1SYKJAK2 | |
| SCHEMBL14723389 | 0.77 | NISCH (0.36) | IGF1RNEK1KMT2APAK4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586234-A | CDKL 3-targeted small molecule inhibitor HZ1 and derivative HZ1-X thereof | 盛韧 | 2024-02-23 | — | — | CN | disclosed |
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | IGF1R 3217/4885NEK1 1292/4885FGFR1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.